ATPace™

ATPace™ (an investigational liquid intravenous pharmaceutical formulation of ATP) is a proposed product for the acute treatment and diagnosis of certain cardiac arrhythmias (abnormal heart rate). These include paroxysmal supraventricular tachycardia (PSVT), rapid regular heart rate originating in the atria, which is one of the most common forms of arrhythmia, and bardycardia (slow heart rate), which is one of the main causes of syncope (fainting).

Therapeutic Indication: It has been estimated that there are 89,000 new cases/year of PSVT in the US alone. PSVT is one of the most common cardiac arrhythmias. The bradycardic effect of ATP, in particular its blockade of atrio-ventricular nodal (AVN) conduction, has been shown to effectively terminate re-entrant PSVT involving AVN. The Company is pursuing the development of the investigational product for the acute termination of PSVT. Based on data obtained in the Company’s Phase I and II clinical trials and more than 1,000 patients records from other clinical trials, Duska is planning to meet with the FDA to ascertain which additional requirements might be necessary for marketing approval of ATPace™ for the acute treatment of PSVT.

Legend: ATP activates P2X2/3 receptors on vagal sensory nerve terminals in the heart. These nerve terminals are believed to play a mechanistic role in certain types of syncope.

Diagnostic Indication: Duska believes that the bradycardic effect of ATPace™ is much more pronounced in selected groups of patients with syncope of unknown origin or suspected neurally-mediated syncope. Thus, ATPace™ should identify patients with bradycardic syncope who could benefit from cardiac pacemaker therapy. The Company anticipates that the ATPace™ diagnostic test will be quick, safe, cost-effective and convenient when compared to other current diagnostic alternatives. The only approved diagnostic test that can determine the potential benefits of cardiac pacemaker therapy in patients with recurrent syncope is the Implantable Loop Recorder (ILR), a device that is implanted in the patient chest for several months. ATPace™ has the potential to benefit a significant number of patients whose syncope is currently misdiagnosed and mistreated.

Duska Therapeutics

info@duskatherapeutics.com

Promising New Medicines